Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Jawaharlal Nehru Centre For Advanced Scientific Research currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are handled by 3 distinct examiners across 3 distinct art units. This distribution between actions, examiners, and units suggests that each matter is being prosecuted in a different technical environment within the USPTO. The involvement of 3 distinct art units indicates that the company's research spans multiple specialized fields within the pharmaceutical sector, which may require a diverse set of legal strategies. Practitioners should note that the workload is shared among several individuals.
JEBUTU, MOFOLUWASO SIMILOLUWA is the busiest examiner for this portfolio, holding 1 busiest examiner pending action. Since there are 3 pending office actions in total, the workload is spread across the individuals involved. Practitioners should note that the distinct art units may have different examination timelines or procedural requirements. The 3 pending office actions in Biotechnology & Pharmaceuticals represent the current active prosecution pipeline for the institution, with 1 busiest examiner pending action assigned to the lead examiner. This structure allows for a diversified prosecution strategy where the outcome of one matter is less likely to be influenced by the specific biases of a single examiner. Practitioners can leverage the involvement of 3 distinct art units to identify potential trends in how the USPTO is treating the institution's specific technical niche.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JEBUTU, MOFOLUWASO SIMILOLUWA | 1 | 34.8% | +41.2% |
| CHENG, KAREN | 1 | 76.4% | +26.6% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18565911 | SMALL MOLECULE MODULATOR TARGETING A RARE HISTONE MODIFICATION REGULATING ADIPOGENESIS AND PHARMACEUTICAL FORMULATION THEREOF | CHENG, KAREN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18006578 | NAPHTHALENE MONOIMIDE COMPOUNDS AND METHODS THEREOF | RZECZYCKI, PHILLIP MATTHEW | 5d overdue |
| 18684615 | A CATALYST, ITS APPLICATION IN PRODUCTION OF HYDROGEN | JEBUTU, MOFOLUWASO SIMILOLUWA | — |
| 18565911 | SMALL MOLECULE MODULATOR TARGETING A RARE HISTONE MODIFICATION REGULATING ADIPOGENESIS AND PHARMACEUTICAL FORMULATION THEREOF | CHENG, KAREN | — |
| Art Unit | Apps |
|---|---|
| 1795 | 1 |
| 1623 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18684615 | A CATALYST, ITS APPLICATION IN PRODUCTION OF HYDROGEN | JEBUTU, MOFOLUWASO SIMILOLUWA | 1795 | §112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18565911 | SMALL MOLECULE MODULATOR TARGETING A RARE HISTONE MODIFICATION REGULATING ADIPOGENESIS AND PHARMACEUTICAL FORMULATION THEREOF | CHENG, KAREN | 1623 | §102§103§112 | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18006578 | NAPHTHALENE MONOIMIDE COMPOUNDS AND METHODS THEREOF | RZECZYCKI, PHILLIP MATTHEW | 1625 | §112 | Non-Final OA | 5d overdue | Pending | Jan 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJawaharlal Nehru Centre For Advanced Scientific Research has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Mofoluwaso Similoluwa Jebutu has the most, with 1 of Jawaharlal Nehru Centre For Advanced Scientific Research's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
